Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Y2 LCRS Pharmacology and Therapeutics > vascular system > Flashcards

vascular system Flashcards

thrombosis: explain how a thrombus can form within a vein and identify the drugs used to treat deep vein thrombosis and pulmonary embolism

1
Q

3 initial stages of thrombosis (small-scale thrombin production)

A

tissue factor -> prothrombinase complex -> antithrombin (AT-III)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

initial stages of thrombosis (coagulation): tissue factor

A

tissue factor bearing cells activate factors X and V, forming a prothrombinase complex (fVa and fXa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

initial stages of thrombosis (coagulation): prothrombinase complex

A

prothrombinase complex activates factor II (prothrombin), creating factor IIa (thrombin); initiation stage of coagulation cascade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

initial stages of thrombosis (anticoagulation): antithrombin (AT-III)

A

AT-III inactivates fIIa and fXa, regulating thrombin levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

4 mechanisms anticoagulants use to treat initial stages of thrombosis (first line of treatment); anticoagulants is generic term for drugs treating thrombosis, and specific term which targets coagulation factors

A

inhibit fIIa (same as antithrombin in body), inhibit fXa, increase activity of AT-III, reduce levels of other factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

example of fIIa inhibitor, and administration

A

dabigatran (direct-acting oral; causes GI bleeding)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

example of fXa inhibitor, and administration

A

rivaroxaban (oral; maintenance treatment for DVT and PE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

2 classes of anticoagulants that increase activity of AT-III (fast onset of action, but not orally available)

A

heparin, low-molecular weight heparins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

heparin administration and effects

A

IV, SC; activates AT-III and decreases fIIa and fXa (given for initial PE interim treatment - more effective than dalteparin so used in PE vs DVT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

low-molecular weight heparins example and effects

A

dalteparin (given initially as DVT or PE interim treatment, as work quickly); activate AT-III and decrease fXa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what factors is vitamin K required for

A

II, VII, IX, X

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

name a vitamin K antagonist, which therefore reduces levels of other factors, and administration and time of onset

A

warfarin (indirectly-acting oral, so slow onset of action (5-7 days) - maintenance treatment for DVT and PE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

in physiology, what are anti-coagulants balanced with, and how does change in thrombogenic conditions e.g. DVT/pulmonary embolism

A

balanced with pro-coagulants, but in thrombogenic conditions, pro-coagulants are higher than anti-coagulants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

3 risk factors of Virchow’s triad (increase likelihood of thrombus formation)

A

rate of blood flow, consistency of blood, blood vessel wall integrity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

in DVT/pulmonary embolism, describe rate of blood flow

A

slow/stagnating (e.g. due to immobility), with no replenishment of anti-coagulant factors and balance adjusted in favour of coagulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

in DVT/pulmonary embolism, describe consistency of blood

A

(not viscosity); natural imbalance between procoagulation (II, VII, IX, X) and anticoagulation factors; typically genetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

in DVT/pulmonary embolism, describe blood vessel wall integrity, and how hypertension increases risk of damage

A

damaged endothelia, so blood exposed to procoagulation factors; common in hypertension as blood hits endothelial cells more regularly, so more likely to get damaged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

presentation of DVT and pulmonary embolism

A

swollen leg with pitting oedema and local tenderness (DVT) e.g. following immobility -> if embolises in lung (PE), chest pain, dyspnoea and tachypnoea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

investigations of DVT

A

2-level Wells score (survey out of 10; higher the score, more likely the DVT); D-dimer test (tests for fibrin degradation products in blood); vein scan; confirmed by US

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

investigations for PE

A

CTPA (computed tomographic pulmonary angiography)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

amplification stage of thrombosis: what does fIIa (thrombin) do

A

activates platelets

22
Q

amplification stage of thrombosis: what do activated platelets do

A

change shape and attach to other platelets, forming occlusion

23
Q

amplification stage of thrombosis: what does thrombin (fIIa) bind to on platelets

A

binds to protease-activated receptor (PAR) on platelet surface; PAR antagonists exist but not widely used

24
Q

amplification stage of thrombosis: what does PAR activation of platelets lead to

A

rise in IC Ca2+ from internal stores, causing shape change (contraction, forming stellate appearance)

25
Q

amplification stage of thrombosis: what does IC Ca2+ rise result in

A

exocytosis of ADP (paracrine and autocrine effect) from dense granules

26
Q

amplification stage of thrombosis: what does ADP do in platelets (autocrine effect)

A

activates P2Y12 receptors, which cause platelet activation and aggregation

27
Q

amplification stage of thrombosis: what does PAR activation in platelets liberate

A

arachidonic acid (AA)

28
Q

amplification stage of thrombosis: what does cyclo-oxygenase (COX) convert arachidonic acid (AA) into

A

thromboxane A2 (TXA2)

29
Q

amplification stage of thrombosis: what does TXA2 activation lead to being expressed on platelet surface

A

GPIIb/IIIa integrin receptors

30
Q

amplification stage of thrombosis: what are GPIIb/IIIa integrin receptors involved in

A

platelet aggregation

31
Q

what drug prevents platelet activation/aggregation by antagonising ADP (P2Y12) receptor, and administration

A

clopidogrel (oral; example of antiplatelet therapy given to treat NSTEMI as partially blocked)

32
Q

what drug inhibits production of TXA2 by being an irreversible inhibitor of COX-1, and administration

A

low dose aspirin (oral: high doses are no more effective but cause more side effects; example of antiplatelet therapy given to treat NSTEMI as partially blocked)

33
Q

what drug prevents platelet aggregation by antagonising GPIIb/IIIa integrin receptors, and administration

A

abciximab (IV, SC: limited use and only by specialists - monoclonal antibody)

34
Q

presentation of (N)STEMI

A

chest pain, SOB, sweating, dizziness and chest pain

35
Q

investigation of (N)STEMI

A

(no) change in ECG, increased troponin (breakdown of cardiac tissue, indicating MI)

36
Q

collective term of anticoagulants and antiplatelets

A

blood thinners

37
Q

propogation stage of thrombosis: what is generated

A

fibrin strands

38
Q

propogation stage of thrombosis: what do activated platelets cause

A

large-scale thrombin production

39
Q

propogation stage of thrombosis: how are fibrin strands created

A

fIIa binds to fibrinogen and converts it to fibrin strands

40
Q

what drugs do not remove pre-formed clots (only prevent clot formation, so not useful in MI or stroke)

A

anticoagulants, antiplatelets

41
Q

what drug class does remove pre-formed clots, and when are they used

A

thrombolytics (clot-busters), given if ischaemic stroke (occlusion due to thrombis formation in atria e.g. due to atrial fibrillation and embolised to cerebral arteries, but not category of white or red thrombus as in lumen of artery)

42
Q

how do thrombolytics work

A

convert plasminogen to plasmin, which is a protease that degrades fibrin

43
Q

example of a recombinant tissue type plasminogen activator (rt-PA), and administration

A

alteplase (IV), given as thrombolytic therapy for ischaemic stroke and STEMI (first line treatment to bust clot, then treat with antiplatelets and anticoagulants)

44
Q

presentation of stroke

A

headache, dizziness, loss of coordination and numbness in face, arms and legs

45
Q

invesitgation for stroke

A

serum glucose and electrolytes (normal range), CT scan (eliminate possibility of haemorrhagic stroke to diagnose ischaemic stroke)

46
Q

initiation, amplification and propagation conditions

A

all 3 stages occur in all conditions (DVT, PE, MI, stroke)

47
Q

DVT and PE general treatment

A

anticoagulants

48
Q

NSTEMI and atherosclerosis general treatment

A

antiplatelets

49
Q

stroke and subsequent rupture of atherosclerotic plaque general treatment

A

thrombolytics

50
Q

haemostasis vs thrombosis

A

physiological formation of blood clot vs pathological formation of blood clot

51
Q

side effect profile of anticoagulants, antiplatelets and thrombolytics

A

excessive bleeding

Y2 LCRS Pharmacology and Therapeutics (68 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions